Koumpa Foteini Stefania, Xylas Diamantis, Konopka Maciej, Galea Dieter, Veselkov Kirill, Antoniou Anthony, Mehta Akash, Mirnezami Reza
Department of Surgery, Brighton & Sussex University Hospitals NHS Trust, Eastern Road, Brighton BN2 5BE, UK.
Department of Surgery, Basildon & Thurrock University Hospitals NHS Foundation Trust, Nethermayne, Basildon, Essex SS16 5NL, UK.
Gastroenterol Res Pract. 2019 Apr 1;2019:5180895. doi: 10.1155/2019/5180895. eCollection 2019.
Colorectal peritoneal metastases (CPM) are associated with abbreviated survival and significantly impaired quality of life. In patients with CPM, radical multimodality treatment consisting of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated oncological superiority over systemic chemotherapy alone. In highly selected patients undergoing CRS + HIPEC, overall survival of over 60% has been reported in some series. These are patients in whom the disease burden is limited and where the diagnosis is made at an early stage in the disease course. Early diagnosis and a deeper understanding of the biological mechanisms that regulate CPM are critical to refining patient selection for radical treatment, personalising therapeutic approaches, enhancing prognostication, and ultimately improving long-term survivorship. In the present study, we outline three broad themes which represent critical future research targets in CPM: (1) enhanced radiological strategies for early detection and staging; (2) identification and validation of translational biomarkers for diagnostic, prognostic, and therapeutic deployment; and (3) development of optimized approaches for surgical cytoreduction as well as more precise strategies for intraperitoneal drug selection and delivery. Herein, we provide a contemporary narrative review of the state of the art in these three areas. A systematic review in accordance with PRISMA guidelines was undertaken on all English language studies published between 2007 and 2017. In vitro and animal model studies were deemed eligible for inclusion in the sections pertaining to biomarkers and therapeutic optimisation, as these areas of research currently remain in the early stages of development. Acquired data were then divided into hierarchical thematic categories (imaging modalities, translational biomarkers (diagnostic/prognostic/therapeutic), and delivery techniques) and subcategories. An interactive sunburst figure is provided for intuitive interrogation of the CPM research landscape.
结直肠腹膜转移(CPM)与生存期缩短和生活质量显著受损相关。在CPM患者中,由减瘤手术(CRS)联合腹腔内热灌注化疗(HIPEC)组成的根治性多模式治疗已显示出比单纯全身化疗具有肿瘤学优势。在一些系列研究中,报道了部分经过严格筛选接受CRS+HIPEC治疗患者的总生存率超过60%。这些患者的疾病负担有限,且在疾病进程的早期阶段就得到了诊断。早期诊断以及对调节CPM的生物学机制有更深入的了解,对于优化根治性治疗的患者选择、个性化治疗方法、改善预后以及最终提高长期生存率至关重要。在本研究中,我们概述了三个广泛的主题,它们代表了CPM未来关键的研究目标:(1)增强早期检测和分期的放射学策略;(2)识别和验证用于诊断、预后和治疗的转化生物标志物;(3)开发优化的手术减瘤方法以及更精确的腹腔内药物选择和给药策略。在此,我们对这三个领域的最新进展进行了当代叙述性综述。根据PRISMA指南,对2007年至2017年间发表的所有英文研究进行了系统综述。体外和动物模型研究被认为有资格纳入与生物标志物和治疗优化相关的部分,因为这些研究领域目前仍处于早期发展阶段。然后将获取的数据分为分层主题类别(成像模式、转化生物标志物(诊断/预后/治疗)和给药技术)和子类别。提供了一个交互式旭日图,以便直观地审视CPM研究领域。